KORU Medical Systems to Present Two Abstracts at the Immunoglobulin National Society 2023 National Conference

Rhea-AI Summary

KORU Medical Systems to present two abstracts at the Immunoglobulin National Society 2023 National Conference

Positive

• KORU Medical Systems will present two abstracts at the IGNS' 12th National Conference, showcasing their innovative approaches to enhance infusion experience and patient preference for home-based subcutaneous immunoglobulin therapy.

Negative

• None.

MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, is pleased to announce its participation in the Immunoglobulin National Society (“IGNS”) 2023 National Conference, taking place in Denver, Colorado from October 5^th to 8^th. KORU Medical will present two abstracts during the conference, furthering its commitment to advancing research and development in the field of immunodeficiency therapies.

The first abstract, titled "Optimizing Infusion Time in Patients with Primary Immunodeficiency Disease Using Home-Based Subcutaneous Immunoglobulin Infusion Therapy," explores the innovative approaches and techniques developed by KORU Medical to enhance the infusion experience for patients with primary immunodeficiency diseases. By streamlining and optimizing infusion times, KORU Medical aims to improve treatment compliance while maintaining the highest standards of patient care.

The second abstract, "Factors Contributing to Patient Preference for Home-Based Subcutaneous Immunoglobulin Therapy," delves into the patient perspective and investigates the various factors that contribute to patients' preference for home-based subcutaneous immunoglobulin therapy. Understanding patient preferences is crucial in designing patient-centered treatment strategies, and KORU Medical is committed to delivering solutions that prioritize patients' comfort, convenience, and overall well-being.

"We are thrilled to have two abstracts accepted for presentation at the IGNS’ 12th National Conference," said Brent Rutland, Vice President, Medical Affairs at KORU Medical. "At KORU Medical, we firmly believe in making a positive impact on patients' lives, and these abstracts reflect our dedication to advancing the field of large volume subcutaneous drug delivery. By optimizing the time and efforts patients with immune deficiencies spend infusing their life-improving therapies, we aim to enhance their quality of life and ensure they receive the best possible care."

The posters featuring the abstracts will be presented on Saturday, October 7^th, providing an opportunity for conference attendees to gain valuable insights into KORU Medical's research and development efforts. KORU Medical representatives will also be available throughout the conference to engage in discussions, share expertise, and explore potential collaborations with healthcare professionals and researchers.

About KORU Medical Systems

KORU Medical Systems develops, manufactures, and commercializes innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients around the world. The FREEDOM™ Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements and can be identified by words such as "will" and "aim". Actual results may differ materially from these statements due to potential risks and uncertainties such as those included under the captions "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, which are on file with the SEC and available on our website at www.korumedical.com/investors and on the SEC website at www.sec.gov. All information provided in this release and in the attachments is as of October 5, 2023. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231005334972/en/

Investor Contact:

Greg Chodaczek

347-620-7010

investor@korumedical.com

Source: KORU Medical Systems, Inc.

FAQ

What is KORU Medical Systems presenting at the IGNS conference?

KORU Medical Systems is presenting two abstracts at the IGNS conference, focusing on optimizing infusion time and factors contributing to patient preference for home-based subcutaneous immunoglobulin therapy.

What is the goal of KORU Medical's research and development efforts?

The goal is to enhance the infusion experience for patients with primary immunodeficiency diseases and prioritize patients' comfort, convenience, and overall well-being.

When and where is the IGNS conference taking place?

The IGNS conference is taking place in Denver, Colorado from October 5th to 8th.

What can conference attendees expect from KORU Medical at the conference?

Conference attendees can expect to gain valuable insights into KORU Medical's research and development efforts through the presented abstracts and engage in discussions with KORU Medical representatives.

What is the focus of KORU Medical's abstracts?

The first abstract focuses on optimizing infusion time for patients with primary immunodeficiency disease, while the second abstract delves into factors contributing to patient preference for home-based subcutaneous immunoglobulin therapy.